menu
    • menu
    [{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Gedeon Richter","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Gedeon Richter"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Apadenoson","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Forest Laboratories \/ PPD","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ PPD"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forest Laboratories \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ AstraZeneca"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forest Laboratories \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ AstraZeneca"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forest Laboratories \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ AstraZeneca"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Immunology","graph2":"Phase I","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ceftazidime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ceftazidime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ceftazidime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ceftazidime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ceftazidime","moa":"Bacterial penicillin-binding protein","graph1":"Oncology","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ceftazidime","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ceftazidime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"UT Southwestern Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Metoprolol Succinate","moa":"Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"UT Southwestern Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Metoprolol Succinate","moa":"Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"9","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Phenomix Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dutogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Phenomix Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Phenomix Sciences"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2011","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Forest Laboratories \/ Merz Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Merz Pharma"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Forest Laboratories \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Forest Laboratories \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Forest Laboratories \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Forest Laboratories \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Azimilide Dihydrochloride","moa":"KCNH2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Levomilnacipran","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Levomilnacipran","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Levomilnacipran","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Levomilnacipran","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Levomilnacipran","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Immunology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Immunology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Insert","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"CYPRESS BIOSCIENCE","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ CYPRESS BIOSCIENCE","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ CYPRESS BIOSCIENCE"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"CYPRESS BIOSCIENCE","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ CYPRESS BIOSCIENCE","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ CYPRESS BIOSCIENCE"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"CYPRESS BIOSCIENCE","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ CYPRESS BIOSCIENCE","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ CYPRESS BIOSCIENCE"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran HCl","moa":"Norepinephrine transporter | Serotonin transporter","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Milnacipran HCl","moa":"Norepinephrine transporter | Serotonin transporter","graph1":"Neurology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"7","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"UT Southwestern Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vilazodone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vilazodone Hydrochloride","moa":"Serotonin transporter | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vilazodone Hydrochloride","moa":"Serotonin 1a (5-HT1a) receptor||Serotonin transporter | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Nitroglycerin","moa":"Soluble guanylate cyclase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"Bacterial ribosome||Topoisomerase IV | DNA gyrase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"Topoisomerase IV | DNA gyrase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"EUR-1008","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"EUR-1008","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"EUR-1008","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"University of Florida","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"EUR-1066","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ University of Florida","highestDevelopmentStatusID":"6","companyTruncated":"Forest Laboratories \/ University of Florida"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"EUR-1100","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2011","type":"Inapplicable","leadProduct":"Lactobacillus Fermentum","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Nebivolol Plus Lifestyle Modification","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Forest Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Forest Laboratories"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Keith A. Rodvold","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forest Laboratories \/ Keith A. Rodvold","highestDevelopmentStatusID":"6","companyTruncated":"Forest Laboratories \/ Keith A. Rodvold"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Olayemi Osiyemi MD","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Olayemi Osiyemi MD","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Olayemi Osiyemi MD"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Basim Asmar","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Basim Asmar","highestDevelopmentStatusID":"6","companyTruncated":"Forest Laboratories \/ Basim Asmar"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Martin M. Miner, MD","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Martin M. Miner, MD","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Martin M. Miner, MD"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Lidia Szczepaniak","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Lidia Szczepaniak","highestDevelopmentStatusID":"6","companyTruncated":"Forest Laboratories \/ Lidia Szczepaniak"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Jack Rubinstein","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Jack Rubinstein","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Jack Rubinstein"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Sriram Ramaswamy","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Sriram Ramaswamy","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Sriram Ramaswamy"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Norman Harden","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Pill","sponsorNew":"Forest Laboratories \/ Norman Harden","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Norman Harden"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Valera Bussell","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forest Laboratories \/ Valera Bussell","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Valera Bussell"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Mansoor Ahmed M.D.","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Mansoor Ahmed M.D.","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Mansoor Ahmed M.D."},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Spencer Dorn, MD, MPH","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Spencer Dorn, MD, MPH","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Spencer Dorn, MD, MPH"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gary E. Stein","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"Topoisomerase IV | DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Gary E. Stein","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Gary E. Stein"}]

    Find Clinical Drug Pipeline Developments & Deals by Forest Laboratories

    Menu

    Forest Laboratories

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cebranopadol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Recipient : Tris Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy...

                            Details : Cebranopadol is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Long QT Syndrome.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            May 21, 2019

                            Lead Product(s) : Cebranopadol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Recipient : Tris Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cebranopadol

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Tris Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol

                            Details : Cebranopadol is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            March 20, 2019

                            Lead Product(s) : Cebranopadol

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Tris Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ceftaroline Fosamil

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase IV

                            Sponsor : Olayemi Osiyemi MD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antibiotic Prophylaxis in Open Fractures

                            Details : Ceftaroline is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fractures, Open.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 18, 2016

                            Lead Product(s) : Ceftaroline Fosamil

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase IV

                            Sponsor : Olayemi Osiyemi MD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ceftazidime

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults Wi...

                            Details : Ceftazidime is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 08, 2016

                            Lead Product(s) : Ceftazidime

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cariprazine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressi...

                            Details : Cariprazine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Bipolar Disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 01, 2016

                            Lead Product(s) : Cariprazine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cariprazine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipola...

                            Details : Cariprazine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Bipolar Disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 01, 2016

                            Lead Product(s) : Cariprazine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ceftaroline Fosamil

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Basim Asmar

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ceftaroline Diffusion Into Cerebrospinal Fluid of Children

                            Details : Ceftaroline is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 09, 2015

                            Lead Product(s) : Ceftaroline Fosamil

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Basim Asmar

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linaclotide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase IV

                            Sponsor : Ironwood Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally t...

                            Details : Linaclotide is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Irritable Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            October 29, 2015

                            Lead Product(s) : Linaclotide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase IV

                            Sponsor : Ironwood Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linaclotide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Recipient : Ironwood Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

                            Details : Linaclotide is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Irritable Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            September 24, 2015

                            Lead Product(s) : Linaclotide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Recipient : Ironwood Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Forest Laboratories

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linaclotide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Ironwood Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Wh...

                            Details : Linaclotide is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Constipation.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            September 24, 2015

                            Lead Product(s) : Linaclotide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Ironwood Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth